---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-081480"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-08-21T23:59:59+00:00"
generated_at: "2026-05-17T10:52:29.150221+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quoin shareholders approve increase in shares from 100M to 5B; Sally Lawlor named new CFO

## Summary
- Shareholders approved amendment to increase authorized ordinary shares from 100,000,000 to 5,000,000,000 (50x).
- Sally Lawlor appointed CFO effective Aug 18, 2025; base salary €380,000, bonus up to 50%, pension, health insurance.
- Ms. Lawlor is the niece of CEO Dr. Michael Myers; prior roles at Sebela Pharma, Aptiv Plc, and KPMG.
- Shareholders also approved new Compensation Policy and 2025 Equity Incentive Plan.
- Prior CFO Gordon Dunn's last day was Aug 15, 2025; separation agreement pending.

## SEC filing metadata
- accession: 0001104659-25-081480
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 3.03, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925081480/0001104659-25-081480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925081480/tm2524078d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-081480
- JSON: https://secwatch.observer/filing/0001104659-25-081480.json
- Plain text: https://secwatch.observer/filing/0001104659-25-081480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.